0.00Open0.01Pre Close0 Volume76 Open Interest5.00Strike Price0.00Turnover141.89%IV56.57%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0066Delta0.0044Gamma1149.00Leverage Ratio-0.0015Theta0.0000Rho-7.53Eff Leverage0.0005Vega
Arcutis Biotherapeutics Stock Discussion
Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rubric Capital Management LP(9.38%),David Rosen(9.38%)
Long-term! 😜
1 MINUTE AGO, 8:20 AM EDT
VIA GLOBENEWSWIRE
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types | ARQT Stock News
No comment yet